Department of Internal Medicine, College of Medicine, Chosun University, Gwangju, Republic of Korea.
Department of Internal Medicine and Digestive Disease Research Institute, Wonkwang University School of Medicine, Iksan, Republic of Korea.
Digestion. 2024;105(5):389-399. doi: 10.1159/000539777. Epub 2024 Jun 12.
Delayed bleeding is an important adverse event following colorectal endoscopic submucosal dissection (ESD). However, whether anticoagulants are risk factors for delayed bleeding after colorectal ESD remains debatable.
We retrospectively analyzed 1,708 patients who underwent colorectal ESDs between January 2015 and December 2020 at five academic medical centers in South Korea. We aimed to identify the risk factors for delayed bleeding in patients after colorectal ESD and, in particular, to evaluate the effect of anticoagulants.
Delayed bleeding occurred in 40 of 1,708 patients (2.3%). The risk factors for delayed bleeding were antithrombotic agents (odds ratio [OR], 6.155; 95% confidence interval [CI], 3.201-11.825; p < 0.001), antiplatelet agents (OR, 4.609; 95% CI, 2.200-9.658; p < 0.001), anticoagulants (OR, 8.286; 95% CI, 2.934-23.402; p < 0.001), and tumor location in the rectum (OR, 2.055; 95% CI, 1.085-3.897; p = 0.027). In the analysis that excluded patients taking antiplatelet agents, the delayed bleeding rate was higher in patients taking anticoagulants (1.6% no antithrombotic agents vs. 12.5% taking anticoagulants, p < 0.001). There was no difference in the delayed bleeding rate (4.2% direct oral anticoagulants vs. 25.0% warfarin, p = 0.138) or clinical outcomes according to the type of anticoagulant used.
Anticoagulants use was a risk factor for delayed bleeding after colorectal ESD, and there was no difference in the risk of delayed bleeding based on the type of anticoagulant used. Colorectal ESD in patients receiving anticoagulants requires careful observation and management for delayed bleeding.
延迟性出血是结直肠内镜黏膜下剥离术(ESD)后的一个重要不良事件。然而,抗凝剂是否是结直肠 ESD 后延迟性出血的危险因素仍存在争议。
我们回顾性分析了 2015 年 1 月至 2020 年 12 月在韩国五所学术医疗中心接受结直肠 ESD 的 1708 例患者。我们旨在确定结直肠 ESD 后患者延迟性出血的危险因素,特别是评估抗凝剂的作用。
1708 例患者中有 40 例(2.3%)发生延迟性出血。延迟性出血的危险因素包括抗血栓药物(比值比[OR],6.155;95%置信区间[CI],3.201-11.825;p < 0.001)、抗血小板药物(OR,4.609;95%CI,2.200-9.658;p < 0.001)、抗凝剂(OR,8.286;95%CI,2.934-23.402;p < 0.001)和肿瘤位置在直肠(OR,2.055;95%CI,1.085-3.897;p = 0.027)。在排除使用抗血小板药物的患者的分析中,使用抗凝剂的患者延迟性出血率更高(无抗血栓药物者 1.6% vs. 抗凝剂者 12.5%,p < 0.001)。根据使用的抗凝剂类型,延迟性出血率(直接口服抗凝剂者 4.2% vs. 华法林者 25.0%,p = 0.138)或临床结局均无差异。
抗凝剂的使用是结直肠 ESD 后延迟性出血的危险因素,且使用的抗凝剂类型与延迟性出血的风险无差异。接受抗凝剂治疗的患者行结直肠 ESD 需要密切观察和管理延迟性出血。